1. ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.). (January 2017) Authors: von Laffert, M.; Schirmacher, P.; Warth, A.; Weichert, W.; Büttner, R.; Huber, R.M.; Wolf, J.; Griesinger, F.; Dietel, M.; Grohé, Ch. Journal: Lung cancer Issue: Volume 103(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Erythropoietin exhibit angiogenic potential and the role of erythropoietin receptor in lung cancer cells. (February 2017) Authors: Liu, X.; Huber, R.M.; Kiefl, R. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO-0780 Prognostic value of PD-L1 expression in locally advanced NSCLC treated with chemoradiotherapy. (April 2019) Authors: Gennen, K.; Käsmann, L.; Eze, C.; Dantes, M.; Roengvoraphoj, O.; Taugner, J.; Neumann, J.; Mille, E.; Tufman, A.; Huber, R.M.; Orth, M.; Reu, S.; Niyazi, M.; Belka, C.; Manapov, F. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗